Scientific dermatology and healthy skin visual
Bakunova Dermatology Pipeline

Five dermatology programmes. One advanced delivery platform.

Next-generation dermatology solutions engineered through advanced delivery science, formulation development and disease-relevant biological validation.

Explore the pipeline ↓Partner with us ↗
05Dermatology programmes
100%In vitro & ex vivo completed
NextClinical translation
Development Portfolio

Our dermatology pipeline.

Each programme is designed around a defined dermatology need, a tailored delivery strategy and a clear pathway towards licensing or co-development.

Scientific skin model illustrating acne
BN–001

Acne

Targeted delivery approach for inflammatory and follicular acne pathways.

✓ In vitro & ex vivo studies completed
Scientific skin model illustrating psoriasis
BN–002

Psoriasis

Barrier-focused formulation strategy for localised inflammatory skin disease.

✓ In vitro & ex vivo studies completed
Scientific skin model illustrating hyperpigmentation
BN–003

Hyperpigmentation

Precision modulation of melanogenesis with enhanced epidermal delivery.

✓ In vitro & ex vivo studies completed
Scientific skin model illustrating vitiligo
BN–004

Vitiligo

Dermal delivery programme supporting repigmentation-focused development.

✓ In vitro & ex vivo studies completed
Scientific skin model illustrating healthy skin ageing
BN–005

Healthy Skin Ageing

Multi-pathway programme addressing visible ageing and skin resilience.

✓ In vitro & ex vivo studies completed
Developed using Xnova Technology Platform

Ingredient-specific delivery engineering designed around the active, target tissue and intended product objective.

Scientific Validation Framework

Evidence designed to support development decisions.

01

Dermal delivery

Human skin permeation and tissue-retention studies.

02

Biological performance

Disease-relevant cellular efficacy and biomarker pathways.

03

Safety assessment

Irritation, corrosion and cytotoxicity using validated models.

04

Technology differentiation

Integrated evidence connecting formulation design to performance.

Development Pathway

Built for the next stage.

Programmes have completed non-clinical in vitro and ex vivo evaluation and are positioned for clinical translation and strategic partnering.

  1. 01
    Completed

    Technology & formulation

    Delivery-system selection and formulation engineering.

  2. 02
    Completed

    In vitro & ex vivo validation

    Performance, safety and biological relevance.

  3. 03
    Next stage

    Clinical translation

    Clinical study planning and programme advancement.

  4. 04
    Partnering

    Licensing or co-development

    Market adaptation and commercialisation pathways.

Out-Licensing & Co-Development

Advance a Bakunova pipeline asset with us.

Strategic partnerships are invited to support clinical development, market adaptation and commercialisation.

Discuss a programme ↗